抗高血压药物使用与癌风险之间的关联:对高血压的分析
Minji Jung1, Mingyi Li2,3, Jaekyu Shin4
1Department of Urology, Stanford University Medical Center, Stanford, CA, USA. mjjung@stanford.edu.
BMC cancer
|June 6, 2025
概括
使用抗高血压药物 (AHTN) 增加了癌 (KC) 的风险,独立于高血压. 通道阻断剂 (CCB) 在AHTN类中显示出最高的风险,强调了心血管治疗的潜在KC风险.
科学领域:
- 药物监测和癌症流行病学
- 心血管疾病和脏病学
背景情况:
- 新出现的证据表明,使用抗高血压药物 (AHTN) 与癌 (KC) 风险增加之间存在联系.
- 高血压本身就是一种已知的癌症风险因素,这使得评估AHTN的独立效应变得更加复杂.
- 有限的研究已经解开了AHTN使用对KC风险的具体贡献,与潜在的高血压分开.
研究的目的:
- 确定AHTN使用与KC风险之间的关联的综合估计.
- 具体确定AHTN使用对KC风险的独立影响,控制高血压的影响.
主要方法:
- 进行了对观察性研究的元分析,调查了AHTN使用和KC风险,直到2025年1月.
- 采用分层分析来隔离AHTN与高血压的影响,通过比较带有和没有高血压会计的研究.
- 利用随机效应的元分析与可靠的差异估计来计算聚合相对风险 (RR).
主要成果:
- 分析包括39项研究,揭示了当高血压被考虑时,AHTN使用与KC风险增加有关.
- 特定的AHTN类显示高风险:通道阻断剂 (CCB) (RR 1.40),利尿剂 (RR 1.36) 和未分类的AHTN (RR 1.40).
- 持续时间-反应分析支持了主要发现,表明了潜在的剂量依赖关系.
结论:
- 使用抗高血压药物与患癌的风险更高有关,即使在控制高血压时也是如此.
- 通道阻断剂 (CCB) 在研究的AHTN类中显示出与KC风险增加的最显著关联.
- 这些发现强调了在管理心血管健康的同时,需要考虑与各种AHTN类相关的潜在癌风险.
更多相关视频
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.7K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
512
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
473
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
473
01:18Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:25Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600